13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001595725
Total reported value
$2.0B
$2.0B
113 檔
38.4%
The Q1 2024 SEC filing reveals that Rock Springs Capital Management LP held a total portfolio value of $2.0B, covering 113 public equity positions.
During Q1 2024, Rock Springs Capital Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 2655787D | Blueprint Medicines CORP | Stock-Other | 6.02% | — | -13.30% | |
| 2 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 3.91% | — | -11.03% | |
| 3 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 3.69% | +0.02% | -11.80% | |
| 4 | EVH | Evolent Health Inc - A | Stock-Other | 3.32% | +0.30% | +0.69% | |
| 5 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.02% | -0.75% | — | |
| 6 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 2.89% | +0.44% | — | |
| 7 | PEN | Penumbra Inc | Stock-Healthcare | 2.86% | -0.55% | -6.05% | |
| 8 | IDXX | Idexx Laboratories Inc | Stock-Healthcare | 2.46% | — | — | |
| 9 | ACHC | Acadia Healthcare Co Inc | Stock-Other | 2.37% | -0.10% | EXIT | |
| 10 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.29% | -1.85% | — | |
| 11 | BSX | Boston Scientific CORP | Stock-Healthcare | 2.14% | -0.81% | — | |
| 12 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 2.10% | +0.08% | +1.19% | |
| 13 | DXCM | Dexcom Inc | Stock-Healthcare | 2.10% | -0.19% | +0.13% | |
| 14 | LLY | Eli Lilly & Co | Stock-Healthcare | 2.04% | +0.43% | +48.56% | |
| 15 | FRPT | Freshpet Inc | Stock-Consumer Staples | 1.95% | — | — | |
| 16 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 1.94% | -0.69% | +44.29% | |
| 17 | EXK | Exact Sciences CORP | Stock-Materials | 1.86% | — | +3.95% | |
| 18 | ALGN | Align Technology Inc | Stock-Healthcare | 1.83% | — | — | |
| 19 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 1.68% | +0.21% | — | |
| 20 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.57% | -0.14% | EXIT | |
| 21 | KYMR | Kymera Therapeutics Inc | Stock-Other | 1.55% | +0.10% | — | |
| 22 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.46% | +0.05% | +41.51% | |
| 23 | PHR | Phreesia Inc | Stock-Other | 1.44% | +0.05% | +7.17% | |
| 24 | PODD | Insulet CORP | Stock-Healthcare | 1.39% | — | -25.88% | |
| 25 | WST | West Pharmaceutical Services | Stock-Healthcare | 1.38% | — | — | |
| 26 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.37% | -0.61% | — | |
| 27 | AGL | agilon health, inc. | Stock-Other | 1.37% | — | +2.38% | |
| 28 | ✓ | Merus N V | Stock-Other | 1.31% | — | +31.48% | |
| 29 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 1.31% | -0.63% | -18.01% | |
| 30 | HUM | Humana Inc | Stock-Healthcare | 1.30% | — | -52.45% | |
| 31 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 1.18% | +0.14% | +0.28% | |
| 32 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 1.16% | -0.25% | +11.83% | |
| 33 | SWAVUSD | Shockwave Medical Inc | Stock-Other | 1.12% | — | +12.50% | |
| 34 | ASND | Ascendis Pharma A/S | Stock-Other | 1.11% | -2.62% | EXIT | |
| 35 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.08% | — | — | |
| 36 | AZTA | Azenta Inc | Stock-Other | 1.06% | -0.21% | +36.90% | |
| 37 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 1.05% | -0.46% | +17.66% | |
| 38 | OLN | Olin Corporation | Stock-Materials | 1.00% | — | — | |
| 39 | IMVT | Immunovant Inc | Stock-Other | 0.94% | — | +16.97% | |
| 40 | ACCDUSD | Accolade Inc | Stock-Other | 0.94% | — | +1.58% | |
| 41 | AKRO | Akero Therapeutics Inc | Stock-Other | 0.83% | — | +20.24% | |
| 42 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.80% | — | +187.07% | |
| 43 | PCRX | Pacira Biosciences Inc | Stock-Other | 0.78% | — | — | |
| 44 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 0.76% | +3.17% | +27.38% | |
| 45 | LFST | Lifestance Health Group Inc | Stock-Other | 0.75% | — | +5.40% | |
| 46 | SGRY | Surgery Partners Inc | Stock-Other | 0.75% | -0.08% | — | |
| 47 | WRBY | Warby Parker Inc-class A | Stock-Other | 0.72% | — | +2.55% | |
| 48 | ✓ | Inozyme Pharma Inc | Stock-Other | 0.72% | — | — | |
| 49 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.71% | +0.13% | +31.82% | |
| 50 | LEGN | Legend Biotech Corp-adr | Stock-Other | 0.71% | +0.01% | +1.43% |
According to official SEC Form 13F filings, Rock Springs Capital Management LP reported a total U.S. public equity portfolio value of $2.0B across 113 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including 2655787D, IMCR, NBIX) accounted for 38.4% of total reported equity market value during Q1 2024.
During Q1 2024, Rock Springs Capital Management LP's top holdings by market value included 2655787D (6.0%)、IMCR (3.9%)、NBIX (3.7%). The largest single position, 2655787D, represented 6.0% of total portfolio value.
In Q1 2024, Rock Springs Capital Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.